

Cumulative Index 1987

Volume 13

April	RHEUMATIC DISEASES OF CHILDHOOD, pages 1-178
August	PATHOGENESIS OF CHRONIC INFLAMMATORY ARTHRITIS, pages 179-410
December	IMMUNOLOGY OF THE RHEUMATIC DISEASES, pages 411-605

Note: Page numbers of issues and articles are in **boldface** type.

- Accessory molecules, in activation of T cells, 419-422
- Adjuvant arthritis, animal model for, **307-318**
 pathogenesis of, 296
 cross-reactive autoimmunity in, 344-345
 cytokines in, 537
 genetic control of, 538-539
 immune response in, 532-535
 immunomodulation in, 535-536
 mechanisms of, 538
 passive transfer experiments in, 536-537
- Aleutian mink disease, 251
- Amiprilose, antiarthritic effects of, 313
- ANA. See *Antinuclear antibodies*.
- Animal models, of arthritis, **307-318**
- Ankylosing spondylitis, HLA and, 471-475
 susceptibility to, restriction fragment length polymorphism in, **353-367**
- Antibodies, anti-DNA, in systemic lupus erythematosus, 570-579
 anti-idiotypic, rheumatoid factor production initiated by, 553-554
 anti-Sm, in systemic lupus erythematosus, 570-571
 polyspecificity in, 574-575
- Antigen S, causing uveitis, 26-27, 29
- Antigen-antibody reactions, in chronic inflammatory arthritis, **179-189**
- Antigens. See also *Human leukocyte antigen*.
 HLA-D region, in juvenile rheumatoid arthritis, 1-6
 in antinuclear antibody induction, 573-576
 ocular, autoimmunity to, 28-29
 causing uveitis, 25-26
 retinal, causing uveitis, 26-27
 rheumatoid factor production initiated by, 553-554
 T cell activation by, **411-430**
 accessory molecules in, 419-422
 signal transduction in, 414-419
 T cell antigen receptor structure in, 411-414
 viral, formation of, 242-243
- Antigen-specific immunosuppression, arthritis pathogenesis and, 314-315
- Antinuclear antibodies, function of, 578-579
 in systemic lupus erythematosus, 37-46, 569-573
 markers for, in uveitis, 22
 production of, **569-581**
 antigen role in, 573-576
 cells in, 576-577
 in systemic lupus erythematosus, 569-573
 mechanisms of, 571-577
 structure of, 577-578
- Arachidonic acid, derivatives of. See *Eicosanoids*.
 metabolism of, in joint destruction, 220
- Arthritis, chronic inflammatory. See *Chronic inflammatory arthritis*; *Rheumatoid arthritis*.
- Arthritis Impact Measurement Scales, adaptation of, to pediatric population, 136
- Arthritogenic factor, 313-314

- Arthrography, traction, 58
- Aspirin, in Kawasaki syndrome, 13-16
- Autoantibodies, in lupus, 512-515
 from somatic mutation, 518-519
 genetic elements associated with, 515-517
 genetic restriction among, 517-518
 in uveitis, 28
- Autoimmunity, in arthritis pathogenesis, cross-reactive, 339-352
 molecular mimicry in, 339-352
 in rheumatoid arthritis, 319-338
 in systemic lupus erythematosus, 37-46
 HLA and, 500-501
 to chromatin, 38-40
 to collagen, HLA and, 490-491
 to ribonucleoproteins, 41-44
- Autologous mixed lymphocyte reaction, 202, 206-207
 in rheumatoid arthritis, 436-438, 455-458
 in systemic lupus erythematosus, 434
- Azathioprine, in lupus nephritis, 47-54
- B cell antigen receptor genes, in autoimmune mice, 512-519
- B cells (B lymphocytes), genomic organization of, in murine lupus, 511-530
 in arthritis pathogenesis, 319-338
 CD5-positive, 328-335
 circulating, 326-328
 sensitized, 325-326
- Bacteria and bacterial products, in arthritis pathogenesis, 293-306, 310, 479-480, 491
 molecular mimicry and, 339-352
 in uveitis, 23-24
 rheumatoid factor production initiated by, 554
- Bone, growth of. See *Growth plate*.
 rheumatoid arthritis effect on, 218
 scintigraphy of, in children, 61-65
- Calcitonin gene-related peptide, inflammation and, 371-374
- Calpactins, in eicosanoid synthesis, 396
- Cardiovascular pathology, in Kawasaki syndrome, 9-11
- Cartilage, constituents of, 216-218
 delineation of, with magnetic resonance imaging, 69
 immune reactions in, 182-186
 loss of, radiography in, 59-61
 similarity of, to bacteria, arthritis pathogenesis and, 310
- Cartilaginous component, of growth plate, 78-88
 hypertrophic zone, 82-88
 proliferative zone, 81-82
 reserve zone, 79-80
- CD2, in activation of T cells, 419-420
- CD4, in activation of T cells, 420-421
- CD8, in activation of T cells, 420-421
 in synovium, in rheumatoid arthritis, 450
- CD28, in activation of T cells, 420
- CD4-positive cells, in synovium, in rheumatoid arthritis, 450
- CD5-positive cells, in rheumatoid arthritis, 328-335
- CD3/Ti complex, 415-418
- Cellular immunity, in chronic inflammatory arthritis, 179-180, 191-213
 in uveitis, 28-29
- Central nervous system, inflammation and, 375-376
- Chemotherapy, in lupus nephritis, 47-54
- Children. See also *Juvenile rheumatoid arthritis*; *Pediatric rheumatology*.
 chronically ill, impacts on families of, 123-131
 in schools, 113-121
 Title V approach and, 105-111
 growth plate in, 75-99
 health status assessment in, 133-140
 joint disease in, radiographic evaluation of, 57-73
 juvenile rheumatoid arthritis in, chronic uveitis and, 19-36
 HLA antigens in, 1-6
 Kashin-Beck disease in, 101-104
 Kawasaki syndrome in, 7-17
 systemic lupus erythematosus in, nephritis in, 47-56
 nucleoprotein autoimmunity and, 37-46
- Chondrocytes, coagulative necrosis of, in Kashin-Beck disease, 102
 in joint destruction, 221-222
- Chromatin, autoimmunity to, 38-40
- Chronic illness, in children, impacts on families of, 123-131
 in schools, 113-121
 Title V approach and, 105-111
- Chronic inflammatory arthritis. See also specific type, e.g., *Rheumatoid arthritis*.
 in Kawasaki syndrome, 9
 pathogenesis of, 531-544
 animal models and, 307-318
 autoimmunity in, 319-338
 biochemical mechanisms in, 215-233
 cellular immunity and, 191-213
 cytokines in, 537
 genetic control of, 538-539
 immune response in, 532-535
 immunomodulation in, 535-536
 intra-articular antigen-antibody reactions in, 179-189
 lentivirus in, 235-247

- lipid mediators in, 385-405
 mechanisms of, 538
 molecular mimicry in, 339-352
 nervous system contributions in, 369-383
 parvovirus in, 249-263
 passive transfer experiments in, 536-537
 proinflammatory microbial products in, 293-306
 restriction fragment length polymorphism in, 353-365
 rubella virus in, 265-274
- Collagen, autoimmunity to, HLA and, 490-491
 immune reactions in, 182-186
 properties of, 216-217
- Collagen arthritis, animal model for, 307-318
 pathogenesis of, cytokines in, 537
 genetic control of, 538-539
 immune response in, 532-535
 immunomodulation in, 535-536
 mechanisms of, 538
 passive transfer experiments in, 536-537
- Collagenase, in pannus, 220
 in proteolysis, 228-229
 in synovial fluid, 219, 223-224
 types of, 223-224
- Colony-stimulating factor, in synovium, in rheumatoid arthritis, 453-454
- Complement mechanism, in immune complex handling, 587-589
- Complete Freund's Adjuvant, causing uveitis, 24-25
- Computed tomography, in children, 65-66
- Corticosteroids, in uveitis, 23
- Costs, in chronic illness, 124
- CRL, in immune complex handling, 587-589
- Cross-reactive autoimmunity, in arthritis pathogenesis, 339-352
- Cross-reactive idiotypes, of rheumatoid factors, 547-552
- Cyclophosphamide, in lupus nephritis, 47-54
- Cytokines, abnormal regulation of, 202-204
 in chronic arthritis pathogenesis, 537
 in synovium, in rheumatoid arthritis, 451-456
- Dendritic cells, in synovial effusion, 197
- Diacylglycerol, in activation of T cells, 416-417
- Dietary fatty acids, eicosanoid synthesis and, 399-402
- DNA probes, in arthritis pathogenesis, 358
- Drugs, systemic lupus erythematosus induced by, HLA and, 501-502
 toxicity to, HLA and, 493
- Education, of chronically ill children, 108, 113-121
 of pediatric rheumatologists, 161-167, 169-173
 history of, 146
- Effusion, synovial. See *Synovial fluid*.
- Eicosanoids, anti-inflammatory agents and, 397-399
 history of, 385-386
 immune cell function and, 392-393
 in dietary marine lipids, 401-402
 inflammation and, 388-392
 leukotrienes as, 387-388
 prostaglandins as, 386-387
 synthesis of, 393-394
 nutritional modification of, 399-401
 regulation of, 394-397
 thromboxanes as, 386-387
 versus platelet activating factor, 393-394
- Endonuclease restriction, in arthritis pathogenesis, 357-358
- Endothelial cells, in pannus, 221
- Endotoxins, in arthritis pathogenesis, 299-300
 in uveitis pathogenesis, 23-25
- Epiphysis, blood supply of, 76-77
- Epitope-specific mechanism (molecular mimicry), in arthritis pathogenesis, 339-352
- Epstein-Barr virus, antigens to, in salivary gland, 279-282
 HLA-DR antigens and, 287-288
 in Sjögren's syndrome pathogenesis, 275-282
 infection by, 276-279
 reactivation of, 285
 replication of, 282-285
- Erythema infectiosum, clinical manifestations of, 254-260
- Extractable nuclear antigens, 41
- Family, of chronically ill child, 123-131
- Fat planes, in joint radiography, 57-58
- Fatty acids, polyunsaturated, in eicosanoid synthesis, 399-402
- Fc receptor mechanisms, immune complexes in, 590-591
- Fibroblast collagenase, 223-224
- "Fifth disease," clinical manifestations of, 254-260

- Fish oil, eicosanoid synthesis and, 399-402
- Foam cells, in pigmented villonodular synovitis, 221
- Freund's complete adjuvant, in arthritis pathogenesis, 296
- Fusarium oxysporum*, in Kashin-Beck disease, 103
- Gamma globulin**, in Kawasaki syndrome, 13-16
- Gamma immunoglobulin rheumatoid factor**, in rheumatoid arthritis pathogenesis, 319-321, 323-328
- Gelatinase, in synovial fluid, 219, 224
- Genes**, antinuclear antibody production and, 577-578
- in chronic arthritis pathogenesis, 538-539
- murine lupus and, 511-530
- of HLA complex, 464-470
- rheumatic disease and, 487-510
- restriction fragment length polymorphism in, 353-367
- rheumatoid factor synthesis and, 555-561
- uveitis and, 20
- German measles. See *Rubella virus*.
- Glucocorticoids, eicosanoid synthesis and, 396
- Glycerol phosphate shuttle, absence of, in growth plate, 86-87
- Goats, tuberculosis-induced arthritis in, 235-237
- Granulocytes, neutrophilic, in synovial fluid, 218
- Growth plate**, 75-99
- cartilaginous component of, 78-88
- hypertrophic zone, 82-88
- proliferative zone, 81-82
- reserve zone, 79-80
- components of, 75-76
- description of, 75
- fibrocartilaginous peripheral structure of, 95, 97
- metaphysis in, 88, 92-93, 95
- vascular supply of, 76-78
- GTP-binding proteins, in activation of T cells, 418
- Handicapped children, services for, 105-111
- Health status assessment, in pediatric rheumatology, 133-140, 152
- Hemophilia, support services for, 109
- Hemophilic synovium, structure of, 220
- High endothelial venules, in synovium, in rheumatoid arthritis, 451
- Hip, computed tomography of, in children, 66
- irritable, radiography of, 58
- ultrasound scanning of, in children, 67-68
- Histocompatibility complex, in arthritis pathogenesis, 308
- restriction fragment length polymorphism in, 353-367
- in rheumatic disease, 463-485
- Histones, antibodies to, 39-40
- in chromatin, 38-40
- History, of pediatric rheumatology, 143-147, 155-159
- Human leukocyte antigen (HLA)**, ankylosing spondylitis and, 471-475
- disease predisposition and, 470-481
- Class I, 471-475
- Class II, 475-481
- drug toxicity and, 493
- in arthritis pathogenesis, 354-357, 360-362
- juvenile rheumatoid arthritis and, 6, 480
- rheumatoid arthritis and, 477-480, 487-493
- Sjögren's syndrome and, 480, 502
- systemic lupus erythematosus and, 480-481, 495-502
- Human leukocyte antigen (HLA) complex**, genes of, function of, 464-470
- structure of, 464-470
- rheumatic diseases and, 463-485
- Humoral immunity, in chronic inflammatory arthritis, 179-186
- Hydralazine, systemic lupus erythematosus induced by, 501-502
- antibodies in, 40
- Hypergammaglobulinemia, in lupus, 512-515
- Hypersensitivity, immediate, neuromodulation of, 371
- Hypertrophic zone, of growth plate, 82-88
- Immune complexes**. See also *Human leukocyte antigen (HLA) complex*.
- as phlogistic agents, 583-584
- characterization of, 584-586
- damage from, 583-584
- defective, handling of, 591-592
- handling of, complement mechanisms in, 587-589
- Fc receptor mechanisms in, 590-591
- model system for, 586-587
- in rheumatic diseases, 583-596
- models of, in uveitis, 27
- physicochemical properties of, 584-587
- Immune response**. See also *T cells*.
- in cartilage, 182-186
- in chronic arthritis pathogenesis, 532-535
- Immunity**. See also *Autoimmunity*.
- cellular, in chronic inflammatory arthritis, 179-180, 191-213
- in uveitis, 28-29
- humoral, in chronic inflammatory arthritis, 179-186

- Immunization, for rubella virus, arthritis in, 267-269
- Immunoglobulin G, predictive value of, in lupus, 514
- Immunoglobulins, abnormal production of, in lupus, 512-515
- genomic organization of, in autoimmune mice, 512-515
- high levels of, in uveitis, 28
- in cartilage, 182-186
- rheumatoid factors and, 547-553
- synthesis of, by rheumatoid B cells, 323-324
- in synovial membrane, 180-182
- Immunology. See also *Genes; Immune complexes; Lymphocytes; T cells*.
- abnormalities of, in Kawasaki syndrome, 11-12
- Immunomodulation, in chronic arthritis pathogenesis, 535-536
- Immunosuppression, antigen-specific, arthritis pathogenesis and, 314-315
- Immunosuppressive drugs, in lupus nephritis, in children, 47-56
- Indian mound-builders, osteoarthritis in, 143-144
- Indium scanning, 311
- Infection, in arthritis pathogenesis, molecular mimicry in, 339-352
- viral. See *Virus(es)*.
- Inflammation, in arthritis pathogenesis, 369-377
- lipid mediators in, 385-405
- Inflammatory disease, bone scintigraphy in, 64
- Inositol 1,4,5-triphosphate, in activation of T cells, 416-417
- Interferon, in rheumatoid arthritis, in synovium, 451-457
- T cells and, 439
- in rheumatoid synovitis, 202-203
- Interleukin, in rheumatoid synovitis, 192, 202-207
- Interleukin-1, in activation of T cells, 421-422
- in synovium, in rheumatoid arthritis, 451-456
- Interleukin-2, in activation of T cells, 422-423
- Interleukin-3-like activity, in synovium, in rheumatoid arthritis, 452-456
- Interphalangeal joint swelling, in Kashin-Beck disease, 101-102
- Iron, in arthritis pathogenesis, 311-312
- Irradiation, total lymphoid, in rheumatoid arthritis, 439
- in systemic lupus erythematosus, 434-435
- Joint destruction, biochemical mechanisms of, 215-233
- effector cells in, 218-222
- proteinases in, 222-225
- proteolytic process in, 225-229
- substrates involved in, 215-218
- Juvenile rheumatoid arthritis, etiology of, 19-36
- HLA and, 1-6, 480, 493-495
- long-term outcome in, 151-154
- magnetic resonance imaging in, 69-71
- pathogenesis of, 19-36
- pauciarticular onset of, HLA and, 494-495
- polyarticular onset of, HLA and, 495
- radionuclide scintigraphy in, 62, 64
- systemic onset of, HLA and, 495
- Kashin-Beck disease, 101-104
- Kawasaki syndrome, 7-17
- arthritis in, 9
- cardiovascular pathology in, 9-11
- clinical features of, 8
- immunoglobulin treatment in, 13-16
- immunologic abnormalities in, 11-12
- Keratconjunctiva sicca. See *Sjögren's syndrome*.
- Killer cells, in synovial effusion, 197-198
- in synovium, 201-202
- Knee, magnetic resonance imaging of, 69-70
- radiography of, in children, 60-61
- scintigraphy of, 62
- La nucleoprotein, autoimmunity to, 42-44
- Lens-induced uveitis, 27
- Lentivirus, in arthritis pathogenesis, 235-247
- antigen formation and, 242-243
- characteristics of, 239
- clinical aspects of, 236-237
- pathology of, 237-239
- persistence mechanisms for, 244
- replication of, 239-240, 241-242
- synovial fluid cells in, 243-244
- transmission of, 240-241
- Leukotrienes, anti-inflammatory effects of, 391-392
- biochemistry of, 387-388
- immune cell function and, 393
- Lining cells, synovial, 198-199
- Lipid mediators, in arthritis pathogenesis, 385-405
- Lipomodulins, in eicosanoid synthesis, 396

- Lipopolysaccharides, causing uveitis, 24
in synovium, in rheumatoid arthritis, 451
- Lupus, murine, genetic aspects of, 511-530
- Lupus nephritis, immune complexes with, 585
in children, immunosuppressive drugs in, 47-56
- Lyme disease, arthritis in, 269
- Lymphatic system, irradiation of, in rheumatoid arthritis, 439
in systemic lupus erythematosus, 434-435
- Lymphocytes. See also *B cells*; *T cells*.
activation of, 411-430
autologous reaction of, 202, 206-207
immune functions of, 204-207
in rheumatoid arthritis pathogenesis, 319-338
in subsynovium, 199-202
in synovial fluid, 193-196
in lentivirus-induced arthritis, 243
in synovial membrane, 180-182
in synovium, in rheumatoid arthritis, 450
neuromodulation of, 371-372
regulators of, disturbances of, 431-445
stimulation of, by muramyl peptides, 294-296
- Lymphokines, abnormal regulation of, 202-204
immune functions of, 204-206
- Lymphotoxin, in rheumatoid synovitis, 203
- Macrophages, in synovial fluid, 196-197
in lentivirus-induced arthritis, 243-244
muramyl peptides and, 294-295
viral antigen formation by, 242-243
- Magnetic resonance imaging, in children, 69-71
- Mainstreaming, of disabled children, 108
- Major histocompatibility complex, in arthritis pathogenesis, 308
restriction fragment length polymorphism in, 353-367
- Marine lipids, eicosanoid synthesis and, 399-402
- Mast cell growth factor, in synovium, in rheumatoid arthritis, 453
- Mast cells, in arthritis pathogenesis, 314
in parvus, 221
in synovium, 201
in rheumatoid arthritis, 450
- Maternal and Child Health Programs, 105-111
- Mental retardation, services for, 107
- Metabolism, in growth plate, 85-86
- Metalloproteinase, in synovial fluid, 219, 222-223
proteolysis regulation by, 225-229
- Metaphysis, blood supply of, 77-78
in growth plate, 88, 92-93, 95
- Methotrexate, arthritis pathogenesis and, 309
- Methylprednisolone, in uveitis, 23
- Microorganisms and products, in arthritis pathogenesis, 293-306
molecular mimicry in, 339-352
- Molecular mimicry, in arthritis pathogenesis, 339-352
in rheumatic disease pathogenesis, 474-475
- Monocytes, in synovial fluid, 196-197
in lentivirus-induced arthritis, 243
- Monokines, abnormal regulation of, 202-204
- Morbidity, pain contributing to, 377-378
- Morphology of synovium, versus arthritis type, 310-311
- Muramyl peptide, in arthritis pathogenesis, 294-297
- Mutation, autoantibodies produced by, in lupus, 518-519
- Mycobacterium tuberculosis* antigen, in rheumatoid arthritis, 479-480, 491
- Mycoplasma arthritidis*, causing uveitis, 25
- Mycoplasma products, in arthritis pathogenesis, 300
- Mycotoxins, in Kashin-Beck disease, 103
- Natural killer cells, in synovium, 197-198, 201-202
in rheumatoid arthritis, 450-451
- Necrosis, coagulative, in Kashin-Beck disease, 102
- Nephritis, lupus, immune complexes with, 585
in children, immunosuppressive drugs in, 47-56
- Nervous system, arthritis pathogenesis and, 369-383
- Neurokinins, inflammation and, 374
- Neurons, inflammation and, sympathetic efferent, 375
unmyelinated afferent, 370-375
- Neutrophil collagenase, 223-224
- Neutrophilic granulocytes, in synovial fluid, 218-219
- Nonsteroidal anti-inflammatory drugs, biochemical action of, 397-399
in uveitis, 23
- Nucleoproteins, autoimmunity to, in systemic lupus erythematosus, 37-46
- Nucleosome, 38
- Ocular antigens, autoimmunity to, 28-29
causing uveitis, 27, 29
- Ossification groove, in growth plate, 95-96

- Osteoarthritis, in Indian mound-builders, 143-144
 in Kashin-Beck disease, 102
 Osteomyelitis, scintigraphy of, 62, 64
 Oxidation, in joint destruction, 219
- Pain, morbidity and, 377-378
 Pannus, immunoglobulin removal by, 184
 structure of, 220-221
 Paralysis, joint inflammation and, 376
 Parvovirus, animal, 249-251
 arthropathy and, 249-263
 human, B19, 252-260
 RA-1, 260-261
 incidence of, 252-254
 manifestations of, 254-260
 structure of, 249, 252
- Passive transfer experiments, in chronic arthritis pathogenesis, 536-537
- Pediatric rheumatology. See also *Children*.
 as academic specialty, 161-167
 family impact survey in, 126-131
 fellowship training requirements for, 169-173
 health status assessment in, 133-140
 history of, 143-147, 155-159
 personal perspective of, 155-159
 reflections on, 155-159
 regional centers for, 110, 146
 services for, 109-111
 specialists in, 146
- Peptidoglycan, causing uveitis, 24
 in arthritis pathogenesis, 294-297
 Peptidoglycan-polysaccharide complex, in arthritis pathogenesis, 297-299
 Perichondrial ring, in growth plate, 95-96
 Phosphorylation, of receptors, in T cell activation, 418-419
 Pigmented villonodular synovitis, cells in, 220-221
 Plasma cells, in synovium, in rheumatoid arthritis, 450
 Platelet activating factor, versus eicosanoids, 393-394
 Polycyclophosphamide, in lupus nephritis, 47-54
 Polyspecificity, in antibodies, 574-575
 Pouch, synovial, ultrasound scanning of, in children, 68
 Prednisone, in lupus nephritis, 47-54
 Probes, DNA, in arthritis pathogenesis, 358
 Procainamide-induced lupus, 40, 501-502
 Procollagenase, in proteolysis, 226-227
 Proinflammatory microbial products, in arthritis pathogenesis, 293-306
 Proliferative zone, of growth plate, 81-82
 Prostaglandins, anti-inflammatory effects of, 388-392
 arthritis pathogenesis and, 312-313
 biochemistry of, 386-387
 immune cell function and, 392-393
 synthesis of, dietary polyunsaturated acids and, 399-402
 Protein kinase C, in activation of T cells, 417
 Proteinase. See also *Metalloproteinase*.
 in joint destruction, 219, 222-225
 inhibition of, 229
 Proteoglycan, in cartilage, 183
 properties of, 217-218
 Proteoglycanase, in joint destruction, 225
 Proteolysis, in arthritis, 225-229
 Psychosocial problems, in chronically ill children, 115
- Quality of life, in pediatric patients, 134
- Radiology, in pediatric joint disease, 57-73
 Radionuclide scintigraphy, in children, 61-65
 Rash, in parvovirus infection, 255-257
 in rubella, 267-268
 Reactive arthritis pathogenesis, cross-reactive autoimmunity in, 347-350
 Receptors, Fc, immune complexes and, 590-591
 T cell antigen. See *T cell antigen receptors*.
 Reflex neurogenic inflammation, in arthritis pathogenesis, 370
 Reflex sympathetic dystrophy, inflammation and, 376
 Reserve zone, of growth plate, 79-80
 Restriction endonuclease, in arthritis pathogenesis, 357-358
 Restriction fragment length polymorphism, in arthritis pathogenesis, 353-367
 Retinal antigens, causing uveitis, 26-27
 Rheumatic disease, T cell regulator disturbances in, 431-445
 Rheumatic fever pathogenesis, cross-reactive autoimmunity in, 346-347
 Rheumatoid arthritis, antigen-antibody reactions in, 179-186
 autoimmunity in, 319-338
 autologous mixed lymphocyte reaction in, 436-437
 cellular immunity in, 191-213
 familial, HLA and, 490
 histopathology of, at onset, 447-448
 HLA and, 477-480, 487-493
 immune complexes in, 589
 joint destruction in, biochemical mechanisms of, 215-233

- Rheumatoid arthritis (*Continued*)
 parvovirus isolation in, 260
 pathogenesis of, 447-461
 intra-articular antigen-antibody reactions in, 179-189
 nervous system and, 369-383
 Sjögren's syndrome and, 289-290
 susceptibility to, restriction fragment length polymorphism in, 353-367
 synovium in, cell types in, 449-451
 T cell immunoregulation in, 435-439
- Rheumatoid factor, 545-568
 binding properties of, 546
 cellular origin of, 555
 idiotypes of, 547-552
 immunochemical characteristics of, 546-552
 in arthritis pathogenesis, 308, 319-321, 323-328
 in healthy persons, 553
 incidence of, 552-553
 structure of, 547-552
 synthesis of, 553-554
 by rheumatoid B cells, 323-325
 genetic basis of, 555-561
- Ribonucleoproteins, autoimmunity to, 41-44
- Ro nucleoprotein, autoimmunity to, 42-44
- Rubella virus, clinical manifestations of, 266-267
 congenital anomalies from, 267
 immunization for, arthritis in, 267-269
 in arthritis pathogenesis, 265-274
 structure of, 265-266
- Sacroiliac joint, radiography of, in children, 65-66
- Salivary glands, Epstein-Barr virus in, 275-290
- School, chronically ill children and, 113-121
 health services in, 118-120
- Scintigraphy, radionuclide, in children, 61-65
- Second messenger system, T cell antigen receptor and, 414-417
- Selenium deficiency, in Kashin-Beck disease, 103
- Serine proteinase, in joint destruction, 225
- Sheep, lentivirus-induced arthritis in, 235-237
- Sheppard-Towner Act of 1925, chronically ill children and, 106
- Sjögren's syndrome, HLA and, 480, 502
 pathogenesis of, Epstein-Barr virus in, 275-292
- Slow virus. See *Lentivirus*.
- Sm nucleoprotein, autoimmunity to, 42-44
- Social Security Act of 1935, Title V, chronically ill children and, 105-111
- Somatic mutation, autoantibodies produced by, in lupus, 518-519
- Somatostatin, inflammation and, 371-372
- Spine, juvenile rheumatoid arthritis of, magnetic resonance imaging of, 69
- Spondyloarthropathy, HLA and, 471-475
- Spontaneous arthritis, 308
- Still's disease, HLA and, 495
- Streptococcal cell wall arthritis, animal model for, 307-318
- Stress, arthritis pathogenesis and, 313
 inflammation and, 376-377
- Substance P, inflammation and, 370-375
- Subsynovium, cells in, 199-202
- Suppressor T cells, in systemic lupus erythematosus, 433-434
- Sympathetic efferent neurons, inflammation and, 375
- Synovial fluid, cells in, 193-202, 218-219
 in lentivirus-induced arthritis, 243-244
- Synoviocyte culture system, 307-318
- Synovium, chronic inflammation of, cellular immunity in, 191-213
 in rheumatoid arthritis, cell types in, 449-451
 immunoglobulin synthesis in, 180-182
 T cells in, 437-439
 in rheumatoid disease, microscopy of, 321-323
 lining cells in, 198-199
- Systemic lupus erythematosus. See also *Lupus, murine*.
 antinuclear antibody in, 569-573
 autoantibodies in, HLA and, 497-498
 autologous mixed lymphocyte reaction in, 434
 autoimmune gene in, HLA and, 500-501
 complement component deficiencies in, HLA and, 499-500
 drug-induced, HLA and, 501-502
 familial, HLA and, 495-496
 HLA and, 480-481, 495-502
 immune complexes in, 583, 589, 591-592
 in children, autoimmunity in, 37-46
 lymphoid radiation in, 434-435
 neonatal, HLA and, 498-499
 subacute cutaneous, HLA and, 498-499
 T cells in, 432-435
- T4 (CD4), in activation of T cells, 420-421
- T8 (CD4), in activation of T cells, 420-421
- T11 (CD2), in activation of T cells, 419-420
- T cell antigen receptors, genes of, in autoimmune mice, 519-526
 Cα and Cβ, 519-522
 Vα, 522-523
 Vβ, 522-526

- second messenger systems coupled to, 414-417
- signal transduction by, 414-419
- structure of, 411-414
- T cells**, activation of, 411-430
 - accessory molecules in, 419-422
 - distal events in, 422-423
 - functions of, in rheumatoid arthritis, 436-437
 - genomic organization of, in lupus, 511-530
 - in chronic arthritis pathogenesis, 534-537
 - in juvenile rheumatoid arthritis, 1-6
 - in Kawasaki syndrome, 12
 - in rheumatoid arthritis, in synovium, 437-439
 - in uveitis, 28
 - regulators of, disturbances of, 431-445
 - subsets of, 432
 - in rheumatoid arthritis, 435-439
- T lymphocytes**. See *T cells*.
- Tachykinin, inflammation and, 374
- Technetium-99m hydroxymethylene diphosphate, in scintigraphy, in children, 61
- Tetracycline, antiarthritic effects of, 313
- Thromboxane, biochemistry of, 386-387
- Title V, chronically ill children and, 105-111
- Toxicity, to immunosuppressive drugs, in lupus nephritis, 53-54
- Tp44 (CD28), in activation of T cells, 420
- Tumor necrosis factor, in rheumatoid synovitis, 204, 451
- Ultrasound scanning**, in children, 67-68
- Uveitis**, in juvenile rheumatoid arthritis, 19-36
 - animal models in, 23-27
 - bacterial products in, 25-26, 28-29
 - clinical characteristics of, 20-23
 - histopathology of, 22-23
 - immune complex models in, 27
 - lens-induced, 27
 - ocular antigens in, 25-26, 28-29
 - pathology of, 22
 - population at risk for, 20
 - retinal antigens in, 26-27
 - treatment of, 23
 - viruses in, 25
 - visual outcome of, 21-22
- Vasculitis**, coronary, in Kawasaki syndrome, 13-16
- Vasoactive intestinal peptide, inflammation and, 371-372
- Virus(es)**, in arthritis pathogenesis, lentivirus, 235-247
 - parvovirus, 249-263
 - rubella, 265-274
 - in uveitis, 25
 - rheumatoid factor production initiated by, 554
- World Health Organization**, health definition of, 134
- Wrist radiography, in children, 60-61